文献速递血液净化与透析肾血管病与高血压

2030年肾脏替代治疗展望:减轻透析患者全球心血管负担

The renal replacement therapy landscape in 2030: reducing the global cardiovascular burden in dialysis patients.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

尽管慢性肾脏病和尿毒症病理生理学认识、先进技术应用及肾脏替代治疗新策略均有显著进展,但慢性肾脏病5期透析患者的临床结局仍不理想。鉴于短时间间歇性透析的残余医疗需求未满足,本文提出应重新审视透析实践标准并探索新治疗选择,以提升透析整体效果、减轻治疗相关应激负担。文章围绕五个关键主题提出改善方向,并展望2030年血液透析将更个体化、以心脏保护为核心。

要点

  • 透析患者心血管负担仍高,需重新审视透析实践标准。
  • 五大方向:提升效率与监测、防透析应激、精准钠水管理、无肝素透析、个体化电解质处方。
  • 2030年血透将更个体化,聚焦心脏保护、容量管理、心律失常监测与避免抗凝。

核心结论

  • 慢性肾脏病5期透析患者临床结局仍不理想,需重新审视透析实践标准并提出新治疗选择以提升透析整体效果、减轻治疗相关应激负担。
  • 2030年血液透析将更个体化,重点聚焦心脏保护、容量管理、心律失常监测、避免抗凝及发展更动态的系统以匹配患者当日液体和电解质需求。

研究设计与样本

  • 本文为综述性文章,围绕减少终末期肾病患者心血管风险的可干预治疗组分展开论述。

主要发现

  • 提出五个最重要的可干预主题:提升治疗效率并持续监测透析性能、预防透析诱导的应激、精准处理钠和液体平衡、迈向无肝素透析、个体化电解质处方。

临床怎么用

  • 临床应关注提升透析效率与持续监测透析性能。
  • 临床应重视预防透析诱导的应激。
  • 临床应精准处理钠和液体平衡。
  • 临床应推进无肝素透析。
  • 临床应个体化电解质处方。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the significant progress made in understanding chronic kidney disease and uraemic pathophysiology, use of advanced technology and implementation of new strategies in renal replacement therapy, the clinical outcomes of chronic kidney disease 5 dialysis patients remain suboptimal. Considering residual suboptimal medical needs of short intermittent dialysis, it is our medical duty to revisit standards of dialysis practice and propose new therapeutic options for improving the overall effectiveness of dialysis sessions and reduce the burden of stress induced by the therapy. Several themes arise to address the modifiable components of the therapy that are aimed at mitigating some of the cardiovascular risks in patients with end-stage kidney disease. Among them, five are of utmost importance and include: (i) enhancement of treatment efficiency and continuous monitoring of dialysis performances; (ii) prevention of dialysis-induced stress; (iii) precise handling of sodium and fluid balance; (iv) moving towards heparin-free dialysis; and (v) customizing electrolyte prescriptions. In summary, haemodialysis treatment in 2030 will be substantially more personalized to the patient, with a clear focus on cardioprotection, volume management, arrhythmia surveillance, avoidance of anticoagulation and the development of more dynamic systems to align the fluid and electrolyte needs of the patient on the day of the treatment to their particular circumstances.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Canaud B, Collins A, Maddux F, et al. The renal replacement therapy landscape in 2030: reducing the global cardiovascular burden in dialysis patients. Nephrol Dial Transplant. 2020. PMID: 32162663. doi:10.1093/ndt/gfaa005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。